Ticker brief
ONC
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
5
crowd 14d
-1.1σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-27 · now +0.35 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PersimmonTI | A | -0.57 | 2 | +0.33 |
| @OzmosiHealth | C | · | 1 | +0.25 |
| @BiopharmIQ | B | · | 1 | +0.20 |
| @ScroogeCap | B | +1.34 | 1 | -0.50 |
| @AponiaAnalytics | B | +4.91 | 1 | +0.35 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @AponiaAnalytics | +0.35 | Reviews favorable zanidatamab combination survival data while emphasizing subgroup caveats. | · | tweet ↗ |
| 2026-08-25 | @ScroogeCap | -0.50 | Reports lawmakers urging FDA scrutiny or rejection of Chinese trial data, viewed negatively for ONC and LEGN. | · | tweet ↗ |
| 2026-08-19 | @PersimmonTI | +0.30 | Argues Chinese pharma licensing will persist as capital-starved biotechs meet aging Big Pharma pipelines. | · | tweet ↗ |
| 2026-08-18 | @BiopharmIQ | +0.20 | Biotech news roundup lists trial, regulatory, acquisition and access catalysts with opening moves. | · | tweet ↗ |
| 2026-08-18 | @OzmosiHealth | +0.25 | BeOne and two foundations renewed a partnership to expand BRUKINSA access in lower-income countries. | · | tweet ↗ |
| 2026-08-15 | @PersimmonTI | +0.35 | Strongly bullish commercial thesis for daraxonrasib, supported by compassionate-use demand and a China partnership. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.